The AI boom’s biggest payoff could be better medicines

The rapid expansion of AI technology, from chips and cloud infrastructure to innovative applications, is poised to revolutionize industries and create substantial economic value. At the 2026 World Economic Forum Annual Meeting in Davos, Nvidia CEO Jensen Huang described AI as a five-layer stack, with the application layer being the most crucial, as it turns computational capacity into tangible products, services, and outcomes.

In the healthcare sector, the potential financial and societal returns from AI investment are particularly promising. While U.S. healthcare spending reached $5.3 trillion in 2024, only a fraction of that amount is directly related to drug discovery. However, the development of a medicine that significantly improves patient outcomes can generate value in multiple ways, including enhanced quality of life, reduced need for other forms of care, and substantial returns for the companies involved.

The success of medicines like tirzepatide, which generated over $36 billion in annual sales for Eli Lilly, demonstrates the commercial potential of AI-powered drug development. AI can significantly improve the drug discovery process by ranking possibilities, identifying relationships in large datasets, and designing experiments that yield more useful information.

However, AI alone cannot overcome the inherent challenges in drug discovery, such as scarce data, inconsistent measurements, and the complexity of living systems. The technology works best when computational models are connected to high-quality experimental data and laboratories capable of quickly testing predictions. Despite significant progress in AI model development, evidence of clinically relevant impact in drug discovery remains limited.

Nevertheless, AI-enabled drug discovery offers a promising alternative by focusing on translation and real-world decision-making. Ultimately, breakthroughs enabled by AI in medicine could provide millions of people with more healthy years of life, hope, and meaning, justifying the scale of current AI investment.